FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2727803568> ?p ?o ?g. }

• W2727803568 abstract "Abstract Background As pegylated asparaginase is becoming the preferred first‐line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment. Methods The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG‐asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l ‐asparaginase activity and formation of anti‐PEG‐asparaginase antibodies. A total of 97 evaluable patients (1–17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG‐asparaginase (Oncaspar ® ) 1,000 IU/m²/dose, at 2‐week or 6‐week intervals with a total of 30‐week treatment (Clinical trials.gov. no.: NCT00819351). Results The pharmacological target of treatment ( l ‐asparaginase activity above 100 IU/l) was reached in 612 of 652 (94%) samples obtained 14 ± 2 days after PEG‐asparaginase administration. Mean l ‐asparaginase activity was 338 IU/l. Six patients had l ‐asparaginase activity below 50 IU/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti‐PEG‐asparaginase antibodies, but there was no correlation between anti‐PEG‐asparaginase antibodies and low levels of asparaginase activity. Conclusion We conclude that prolonged first‐line biweekly PEG‐asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti‐PEG‐asparaginase antibodies was not a predictor of l ‐asparaginase activity." @default.
• W2727803568 created "2017-07-14" @default.
• W2727803568 creator A5007917870 @default.
• W2727803568 creator A5061309869 @default.
• W2727803568 creator A5063115909 @default.
• W2727803568 creator A5071720008 @default.
• W2727803568 creator A5074845542 @default.
• W2727803568 creator A5075840216 @default.
• W2727803568 creator A5087892813 @default.
• W2727803568 date "2017-06-29" @default.
• W2727803568 modified "2023-10-16" @default.
• W2727803568 title "Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation" @default.
• W2727803568 cites W1940732706 @default.
• W2727803568 cites W1965542498 @default.
• W2727803568 cites W1972467214 @default.
• W2727803568 cites W1976249433 @default.
• W2727803568 cites W1995473821 @default.
• W2727803568 cites W2005688611 @default.
• W2727803568 cites W2007102329 @default.
• W2727803568 cites W2012808596 @default.
• W2727803568 cites W2016833582 @default.
• W2727803568 cites W2017265604 @default.
• W2727803568 cites W2018374431 @default.
• W2727803568 cites W2038931075 @default.
• W2727803568 cites W2047657755 @default.
• W2727803568 cites W2053852136 @default.
• W2727803568 cites W2054379931 @default.
• W2727803568 cites W2058713665 @default.
• W2727803568 cites W2060824604 @default.
• W2727803568 cites W2061069132 @default.
• W2727803568 cites W2071818770 @default.
• W2727803568 cites W2076057372 @default.
• W2727803568 cites W2080828049 @default.
• W2727803568 cites W2084089666 @default.
• W2727803568 cites W2096489857 @default.
• W2727803568 cites W2100928838 @default.
• W2727803568 cites W2104428172 @default.
• W2727803568 cites W2113512182 @default.
• W2727803568 cites W2117623554 @default.
• W2727803568 cites W2125277492 @default.
• W2727803568 cites W2127153931 @default.
• W2727803568 cites W2144921015 @default.
• W2727803568 cites W2146971143 @default.
• W2727803568 cites W2162448677 @default.
• W2727803568 cites W2169732420 @default.
• W2727803568 cites W2328984806 @default.
• W2727803568 cites W4230372598 @default.
• W2727803568 doi "https://doi.org/10.1002/pbc.26686" @default.
• W2727803568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28660740" @default.
• W2727803568 hasPublicationYear "2017" @default.
• W2727803568 type Work @default.
• W2727803568 sameAs 2727803568 @default.
• W2727803568 citedByCount "28" @default.
• W2727803568 countsByYear W27278035682018 @default.
• W2727803568 countsByYear W27278035682019 @default.
• W2727803568 countsByYear W27278035682020 @default.
• W2727803568 countsByYear W27278035682021 @default.
• W2727803568 countsByYear W27278035682022 @default.
• W2727803568 countsByYear W27278035682023 @default.
• W2727803568 crossrefType "journal-article" @default.
• W2727803568 hasAuthorship W2727803568A5007917870 @default.
• W2727803568 hasAuthorship W2727803568A5061309869 @default.
• W2727803568 hasAuthorship W2727803568A5063115909 @default.
• W2727803568 hasAuthorship W2727803568A5071720008 @default.
• W2727803568 hasAuthorship W2727803568A5074845542 @default.
• W2727803568 hasAuthorship W2727803568A5075840216 @default.
• W2727803568 hasAuthorship W2727803568A5087892813 @default.
• W2727803568 hasConcept C10138342 @default.
• W2727803568 hasConcept C112705442 @default.
• W2727803568 hasConcept C126322002 @default.
• W2727803568 hasConcept C159654299 @default.
• W2727803568 hasConcept C162324750 @default.
• W2727803568 hasConcept C203014093 @default.
• W2727803568 hasConcept C2776694085 @default.
• W2727803568 hasConcept C2778461978 @default.
• W2727803568 hasConcept C2778904437 @default.
• W2727803568 hasConcept C2781107101 @default.
• W2727803568 hasConcept C2909962599 @default.
• W2727803568 hasConcept C54400483 @default.
• W2727803568 hasConcept C71924100 @default.
• W2727803568 hasConcept C90924648 @default.
• W2727803568 hasConcept C98274493 @default.
• W2727803568 hasConceptScore W2727803568C10138342 @default.
• W2727803568 hasConceptScore W2727803568C112705442 @default.
• W2727803568 hasConceptScore W2727803568C126322002 @default.
• W2727803568 hasConceptScore W2727803568C159654299 @default.
• W2727803568 hasConceptScore W2727803568C162324750 @default.
• W2727803568 hasConceptScore W2727803568C203014093 @default.
• W2727803568 hasConceptScore W2727803568C2776694085 @default.
• W2727803568 hasConceptScore W2727803568C2778461978 @default.
• W2727803568 hasConceptScore W2727803568C2778904437 @default.
• W2727803568 hasConceptScore W2727803568C2781107101 @default.
• W2727803568 hasConceptScore W2727803568C2909962599 @default.
• W2727803568 hasConceptScore W2727803568C54400483 @default.
• W2727803568 hasConceptScore W2727803568C71924100 @default.
• W2727803568 hasConceptScore W2727803568C90924648 @default.
• W2727803568 hasConceptScore W2727803568C98274493 @default.
• W2727803568 hasFunder F4320310455 @default.
• W2727803568 hasFunder F4320312281 @default.
• W2727803568 hasIssue "12" @default.

• next